1 The effectiveness of Evodia rutaecarpa hot compress on the recovery of gastrointestinal 2 function after laparoscopic surgery for colorectal cancer: A propensity score-matched 3 retrospective cohort study 4 MiaoXin Huang¹¶, JunMiao Li³¶, Wei Huang³&, YuLin Zhou⁴&, Lei Cai⁴*, Ming Liu²* 5 6 7 ¹Faculty of Health Sciences and Sports, Macao Polytechnic University, Macao SAR, 8 China 9 10 ²Peking University Health Science Center - Macao Polytechnic University Nursing 11 Academy, Macao Polytechnic University, Macao SAR, China 12 ³The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, 13 14 Guangzhou, Guangdong, China 15 16 ⁴The Third Affiliated Hospital of Sun Yat sen University, Guangzhou, Guangdong, 17 China 18 19 #aPeking University Health Science Center - Macao Polytechnic University Nursing 20 Academy, Macao Polytechnic University, Macao SAR, China 21 #bThe Second Affiliated Hospital of Guangzhou University of Chinese Medicine, 22 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Guangzhou, Guangdong Province, China *Corresponding author Email: karryliu@mpu.edu.mo Email: cailei.0105@163.com These authors contributed equally to this work. &These authors also contributed equally to this work.

Abstract

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

Background Although the use of hot compresses with the herbal medicine Evodia rutaecarpa (ER) as a complementary and alternative therapy to promote recovery of postoperative gastrointestinal function is gradually increasing in clinical practice, there is still a lack of relevant empirical studies. Particularly, the role of ER hot compress therapy on gastrointestinal recovery post-laparoscopic surgery for colorectal cancer has not been well investigated. The purpose of this study is to evaluate the efficacy and applicability of ER hot compress therapy for the recovery of postoperative gastrointestinal function. Methods This is a retrospective cohort study. Patients were divided into two cohorts, the ER group and the non-ER group. Propensity score matching(PSM) was introduced to limit confounding, and independent samples t-tests, non-parametric tests, or Chi-squared tests were used to compare these two cohorts. Results A total of 454 patients were included, with 267 (59%) receiving ER hot compress therapy and 187 (41%) not. Following 1:1 PSM, 320 patients were analyzed (160 in each group). Compared to the ER group, patients in the non-ER group had shorter times to return to a semi-liquid diet (p=0.035) and hospital stay (p=0.001), as well as lower hospital costs (p<0.001). Subgroup analyses revealed no statistically significant differences in the length of hospital stay, hospital costs, postoperative time to return to full-liquid diet, or time to return to semi-liquid diet among stage I and II tumor patients,

72 though means and standard deviations were generally lower in the ER group.

Complication incidence showed no significant difference between the two cohorts

before and after PSM.

Conclusions

The use of ER hot packs after laparoscopic surgery in patients with colorectal cancer

has a non-significant effect on the recovery of the gastrointestinal function and, given

the results of the study, it is likely that patients with early-stage tumors may benefit

more. Therefore, healthcare providers need to consider the individualisation,

practicality, and economics of treatment options.

Keywords: Colorectal cancer, Laparoscopy, Evodia rutaecarpa, Hot compress therapy,

Propensity score

Introduction

The World Health Organization (WHO) has released the latest estimates of the global cancer burden, showing that colorectal cancer (CRC) is the third most common cancer worldwide (over 1.9 million cases, 9.6%) and the second leading cause of cancer deaths (over 0.9 million cases, 9.3%)^[1]. In addition, the World Health Organization's colorectal cancer epidemiological data for the whole of 2022 show that Asia ranks first in terms of colorectal cancer incidence, mortality, and 5-year prevalence (colon, rectum), followed by Europe with the second highest share^[2]. Studies have shown that the incidence and mortality of CRC have decreased in some European, Oceanian and North American countries in recent years ^[3-5], but data from the Chinese Cancer

Center in 2022 show that the incidence and mortality of CRC continue to increase [3, 6-7]. Worryingly, the incidence of colorectal cancer is steadily increasing in China and globally in people under the age of 50 [8-14]. Therefore, the prevention and treatment of colorectal cancer are urgent, and various treatment regimes and technologies have emerged. The surgical procedures have been moved from traditional open surgery to laparoscopic surgery and robotic-assisted laparoscopic surgery. However, postoperative colorectal cancer patients still face various challenges. Among them, postoperative gastrointestinal dysfunction (POGD) is one of the common complications of abdominal surgery, including laparoscopic colorectal cancer surgery [15]. The most commonly occurring symptoms of POGD are nausea, vomiting, abdominal distention, postoperative intestinal ileus (POI), gastrointestinal bleeding, and possibly progressive multi-organ failure^[5]. Therefore, a variety of complementary and alternative therapies have been used to help restore gastrointestinal function after surgery, particularly a range of herbal medicines. In the past few years, Evodia rutaecarpa (ER), also known as Wuzhuyu (a type of herbal medicine), has received increasing attention from various health professionals in mitigating discomfort and supporting recovery from POGD. ER was first described more than 2000 years ago in the Shennong Ben Cao Jing (a Chinese book on agriculture and medicinal plants)^[16]. Nowadays, herbal therapy has attracted worldwide attention^[17]. As an herbal remedy with potential value for CRC patients, ER is worth exploring in depth. In China, the use of ER hot compress therapy is becoming increasingly popular...

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

Based on the literature review, a study by Li and his colleagues showed that the evodiamine and the rutaecarpine derived from ER have high permeability and remarkable selective transdermal properties^[18]. Furthermore, Gu and his colleagues stated that sesquiterpenoids have significant pharmacological activities and suggested that the volatile oil of Cornus officinale can pass through PTGS1, PTGS2 and IL-6^[19]. Because of these properties, ER is mixed with coarse salt in equal proportions to make an ER hot compress bag in clinical practice, heated in a microwave oven at medium heat for 4 minutes, and then applied to the patient's navel or Shengue point. In the implementation of complementary and alternative therapies, not only doctors and rehabilitation therapists, but also nurses play an essential role. Therefore, when implementing complementary and alternative therapies, nurses should proactively understand their efficacy and applicability, use scientific and effective nursing practice based on evidence-based nursing, and strive to be patient advocates. Therefore, this retrospective cohort study focused on colorectal cancer patients undergoing laparoscopy to investigate the effect of ER hot compress therapy on the recovery of postoperative gastrointestinal function.

Materials and method

Study design and data source

This was a retrospective cohort study based on the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines (See S1 File.)^[20-21]. The study was approved by the Ethics Committee of Macao Polytechnic University

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

(approval number: FCSD/MSN-0051/2023) and the Institutional Review Board of the Second Affiliated Hospital of Guangzhou University of Chinese Medicine (approval number: ZE2023-459-01), and individual written informed consent was not required. The study was conducted in accordance with the principles of the Declaration of Helsinki, and the investigators collected electronic medical records of colorectal cancer patients who underwent laparoscopic surgery at the Second Affiliated Hospital of Guangzhou University of Chinese Medicine (Guangdong Provincial Hospital of Chinese Medicine) from December 1, 2016 to December 30, 2022, including patient demographics, perioperative data, and other information. Throughout the study, patient data were de-identified (recorded and stored in a coded form).

Study sample

All data was collected from December 21st, 2023 to February 10th, 2024. The study population was selected based on the following inclusion criteria: 1) meet the diagnostic criteria for CRC in the 2017 edition of the Chinese Standards for the Diagnosis and Treatment of CRC and further confirmed by pathological biopsy^[22]; 2) all participants underwent elective standard laparoscopic radical tumor curettage; 3) the age of patients was between 25 and 80 years; 4) participants signed informed consent for surgery and use of complementary and alternative therapies (herbal ER hot iron therapy).

The exclusion criteria for the study were: 1) a confirmed diagnosis of distant metastasis of the tumor; 2) combination with other malignant tumors; 3) physical

disability that prevents cooperation with functional exercises; 4) mental illness or

cognitive impairment that makes communication with the participant difficult; 5) pregnancy or breastfeeding; 6) patients undergoing abdominal surgery within 6 months and having severe intestinal adhesions; 7) patients with unsatisfactory control of the primary medical disease; 8) concurrent other serious organic diseases; 9) preoperative abdominal infection; 10) patients requiring postoperative blood transfusion; 11) patients requiring open surgery or extended radical surgery; 12) undergoing combined abdominal perineal radical rectal cancer surgery (Miles procedure); 13) patients experiencing serious complications within 6 hours of surgery or requiring admission to intensive care after surgery; 14) patients with allergy to herbal ER therapy. Definition and measurement of exposure factors and outcome indicators Patients were divided into two groups according to the exposure factor (i.e. whether they received ER hot compress treatment after laparoscopic surgery for CRC): the ER group and the conventional treatment group (the non-ER group). 1) The non-ER group only received routine postoperative care, including monitoring of vital signs, postoperative fluid restoration, care of drainage tubes and monitoring of drainage fluids, pain relief, surgical wound care and daily care. 2) The ER group received ER hot compress therapy and routine postoperative care. 250 grams of ER (from Guangdong Kangmei Pharmaceutical Co., Ltd.) and 250 grams of coarse salt (Guangzhou Salt Industry Co., Ltd.) were placed in a cotton bag of 18 cm x23 cm and heated in a microwave oven at medium heat for 2 to 3 minutes. The temperature of the ER hot pack was about 60 - 70 °C, and tolerable to the patient.

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

Nurses massage the ER hot pack in a clockwise direction with the Shenque point (navel) as the centre for 20 circles, avoiding the surgical incision. The ER hot compress treatment is usually started 24 hours after surgery, twice a day for 20 minutes each time.

3) Postoperative gastrointestinal outcomes and their measurements: time of first postoperative flatus, time of first postoperative defecation, and time of recovery of postoperative bowel sounds (the actual measurement of the above three items is recorded from the end of the operation to the time when the doctor asks the patient about the event, and it is not possible to calculate the exact time when the patient has the above events), time of full-liquid diet and time of semi-liquid diet (the actual measurement time is from the end of the operation to the time when the doctor gives the order, i.e. the time when the patient starts the full-liquid diet) and the incidence of postoperative gastrointestinal complications (including postoperative nausea and vomiting, abdominal pain and bloating, anastomotic fistula, and bowel paralysis and obstruction).

Covariates

The selection of covariates consists of three steps in this study. First, possible covariates were selected based on the investigator's clinical experience and literature review, including surgical site, tumor stage, history of chronic gastrointestinal disease, intestinal stoma, gender, chronic lung disease, anaemia, hypoproteinaemia, history of abdominal surgery, diabetes mellitus, hypertension, hyperlipidaemia, history of heart disease, history of smoking, history of alcohol consumption, age, BMI, intraoperative bleeding, and operative time. Second, the raw data were statistically analysed to screen

for possible confounders based on the grouping variable (whether ER hot compress therapy was used or not). Third, different caliper values were adjusted in the R language software to analyse which covariates were likely to have an effect on the study results. The main covariates examined were: 1) continuous variables: age and intraoperative bleeding; 2) categorical variables: hyperlipidaemia and tumor stage. Handling of missing data Firstly, the type of data missing from the Electronic Medical Record System(EMR) information was analysed, such as the patient's basic information, BMI, and the time of the patient's first post-operative bowel movement; Secondly, the analysis concluded that the reason for the missing data collected in this study was Missing Completely at Random (MCAR), due to human factors that were not recorded, omitted, or lost, and did not affect the unbiased nature of the sample: 1) it was divided into the following cases, and if there were more, the researcher simply deleted them; 2) if there were fewer missing values, those missing values were filled by interpolation using the mean and the plurality of the missing values. Statistical methods R4.2.3 software and SPSS 27.0 were used for statistical analysis. Measures that conformed to normal distribution and homogeneity of variances were expressed as mean standard deviation (mean \pm SD) and independent t-test was used for comparison between two groups, while those that did not conform to normal distribution were expressed as median (interquartile range), i.e. M (Q1, Q3) and Mann-Whitney U-test was used for comparison between two groups. Count data were expressed as cases (%)

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

and comparisons between two groups were made using the Pearson chi-squared test or Fisher's exact test. All statistical inferences were made using two-tailed tests with a statistically significant test level of α =0.05 and 95% CI for parameter CI estimation. **Propensity score matching** To assess the impact of confounding bias due to non-randomisation in observational studies, propensity score matching (PSM) was proposed in this study^{[23-} ^{24]}. Four variables, tumor stage, hyperlipidaemia, intraoperative bleeding and age, were used as covariates, and the use of ER hot packs was used as a grouping variable(exposure factor). Propensity scores were calculated for each sample using nearest neighbour 1:1 matching and a caliper value of 0.05. In addition, the investigators visually compared the distribution difference of the two data sets before and after matching by plotting distribution plots, density plots, and empirical cumulative distribution function (eCDF) plots, respectively. Sensitivity analysis First, the parameters of the sensitivity analysis were determined, and common parameters included caliper values and matching ratios^[25]. The researcher evaluates and

First, the parameters of the sensitivity analysis were determined, and common parameters included caliper values and matching ratios^[25]. The researcher evaluates and compares the matching results under different caliper values (e.g. selecting different caliper values of 0.02, 0.03, 0.05, 0.1, and 0.2; as well as selecting different matching ratios (e.g. ratio=1 and ratio=2) and also compares the matching results under different matching variables).

Second, the robustness and sensitivity of the PSM results can be assessed by comparing the sample sizes after matching under different parameter settings by

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

statistically analysing the results, and by assessing the distribution of the scores after matching by plotting distribution plots and histograms. It is assumed that the variation of the matching results under different parameter settings and different matching variables is small, which indicates that the matching results are less sensitive to the choice of parameters and have better robustness and sensitivity.

Equilibrium test

Equilibrium tests are used to assess whether the baseline characteristics between the two data groups (ER and non-ER groups) before and after PSM are effectively balanced. Commonly used equilibrium tests include the Standardised Mean Difference (SMD), the Chi-square test, and the t-test^[26-27]. The SMD was used in this study to assess the effect of adjustment. If the SMD value is small (less than 0.1), it means that the matching effect is good, the confounding factors between the two groups have been effectively controlled, and the research results are credible. In addition, SMD plots and histograms were used to visually analyse the baseline distribution of data between the two groups before and after matching.

Subgroup analysis

To further explore the heterogeneity of the samples after PSM, to analyse the variability of different treatments, and to improve the accuracy and reliability of the results, the researchers performed subgroup analyses of the pooled data. Because tumor staging is usually clinically relevant to the patient's postoperative treatment plan. Therefore, according to the American Joint Committee on Cancer (AJCC) cancer

staging system^[28] and the diagnosis of clinicians, tumor staging was divided into different subgroups for analysis.

Results

The process of study population selection

Fig. 1 Flowchart of sample selection

Before PSM

Before matching, there were 267 cases in the ER group and 187 cases in the non-ER group. Statistical analysis was performed on the final 454 patients enrolled (statistical values represent T value, U value, and chi-square value, respectively). This analysis indicated that, firstly, the p-values for age and hyperlipidemia were 0.015 and 0.008, respectively, indicating statistical significance and potential impact on the results. Secondly, compared to the non-ER group, patients in the ER group had higher hospital costs (p < 0.001), longer hospital stays (p < 0.001), and longer time to resume a semiliquid diet after surgery (p = 0.021). The remaining results showed no statistical significance (see Table 1 and S.Table 1) and other additional information is provided in S.Table 2.

Table 1 Baseline data before PSM

Variables	Total	ER group	Non-ER group	n	statistic
Variables	(n = 454)	(n = 267)	(n = 187)	р	Statistic
Surgical Site, n (%)				0.758	0.095

Variables	Total	ER group	Non-ER group	р	atatiatia
variables	(n = 454)	(n = 267)	7) $(n = 187)$		statistic
Colon =1	164 (36.1)	98 (36.7)	66 (35.3)		
Rectum = 2	290 (63.9)	169 (63.3)	121 (64.7)		
Tumor-staging,				0.250	4 104
n (%)				0.250	4.104
I = 1	48 (10.6)	28 (10.5)	20 (10.7)		
II = 2	83 (18.3)	41 (15.4)	42 (22.5)		
III = 3	85 (18.7)	54 (20.2)	31 (16.6)		
unspecified = 4	238 (52.4)	144 (53.9)	94 (50.3)		
HCGD, n (%)				0.697	0.152
NO = 0	170 (37.4)	98(36.7)	72 (38.5)		
YES = 1	284 (62.6)	169 (63.3)	115 (61.5)		
Intestinal stoma,				0.911	0.012
n (%)				0.911	0.012
NO = 0	307 (67.6)	180 (67.4)	127 (67.9)		
YES = 1	147 (32.4)	87 (32.6)	60 (32.1)		
Gender, n (%)				0.960	0.003
Male = 1	247 (54.4)	145 (54.3)	102 (54.5)		

	Total	ER group	Non-ER group		
Variables	(n = 454)	(n = 267)	(n = 187)	p	statistic
Female = 2	207 (45.6)	122 (45.7)	85 (45.5)		
CLD, n (%)				0.947	0.004
NO = 0	297 (65.4)	175 (65.5)	122 (65.2)		
YES = 1	157 (34.6)	92 (34.5)	65 (34.8)		
Anemia, n (%)				0.861	0.031
NO = 0	390 (85.9)	230 (86.1)	160 (85.6)		
YES = 1	64 (14.1)	37 (13.9)	27 (14.4)		
Hypoproteinemia,				0.760	0.093
n (%)				0.700	0.073
NO = 0	422 (93.0)	249 (93.3)	173 (92.5)		
YES = 1	32 (7.0)	18 (6.7)	14 (7.5)		
HAS, n (%)				0.890	0.019
NO = 0	339 (74.7)	200 (74.9)	139 (74.3)		
YES = 1	115 (25.3)	67 (25.1)	48 (25.7)		
Diabetes, n (%)				0.793	0.069
NO = 0	391 (86.1)	229 (85.8)	162 (86.6)		
YES = 1	63 (13.9)	38 (14.2)	25 (13.4)		

Variables	Total	ER group	Non-ER group		statistis
variables	(n = 454)	(n = 267)	(n = 187)	p	statistic
Hypertension, n (%)				0.983	0.000
NO = 0	328 (72.2)	193 (72.3)	135 (72.2)		
YES = 1	126 (27.8)	74 (27.7)	52 (27.8)		
Hyperlipidemia,				0.000	5 0 5 5
n (%)				0.008	7.075
NO = 0	353 (77.8)	196 (73.4)	157 (84.0)		
YES = 1	101 (22.2)	71 (26.6)	30 (16.0)		
HHD, n (%)				0.257	1.284
NO = 0	302 (66.5)	172 (64.4)	130 (69.5)		
YES = 1	152 (33.5)	95 (35.6)	57 (30.5)		
Smoking History,					
n (%)				0.534	0.387
NO = 0	349 (76.9)	208 (77.9)	141 (75.4)		
YES = 1	105 (23.1)	59 (22.1)	46 (24.6)		
Drinking History,					
n (%)				0.728	0.121
NO = 0	401 (88.3)	237 (88.8)	164 (87.7)		

Variables	Total $(n = 454)$	ER group (n = 267)	Non-ER group $(n = 187)$	р	statistic
YES = 1	53 (11.7)	30 (11.2)	23 (12.3)		
Age,Mean±SD	60.31 ± 9.88	59.37 ±10.32	61.65 ± 9.09	0.015	2.433
BMI, Mean \pm SD	22.91 ± 2.99	22.84 ± 3.03	23.01 ± 2.93	0.568	0.572
Intraoperative					
Hemorrhage_ml,	50 (50, 100)	50 (50, 100)	50 (30, 100)	0.841	24696
Median (Q1,Q3)					
Operative Time_h,	4.00(3.46,	4.00(3.50, 4.67)	3.92(3.33, 4.73)	0.491	24018
Median (Q1,Q3)	4.67)	4.00(3.30, 4.07)	3.92(3.33, 4.73)	0.491	2.010
Hospital	50500.15	75.400 (0.)	71212.06		
Costs_CNY,	73733.17 ±	75429.63 ±	71310.96 ±	< 0.001	-4.198
Mean ± SD	10823.33	11426.93	9409.44	0.001	
Length of Hospital					
Stay_d,	15.5 (14, 18)	16 (14, 19)	15 (13, 17)	0.001	20514
Median (Q1,Q3)					
NEBS,	10 (0.16)	16 (12, 20)	0 (0, 0)	<	0
Median (Q1,Q3)	10 (0, 16)	16 (12, 20)	0 (0, 0)	0.001	0
TFPE_d,	1.83 (1.61,	1.05 (1.64.2.63)	1.00 (1.60.2.60)	0.101	22704.5
Median (Q1,Q3)	2.68)	1.85 (1.64, 2.69)	1.80 (1.60, 2.68)	0.101	22706.5

	Total	ER group	ER group Non-ER group		statistic
Variables	(n = 454)	(n = 267)	(n = 187)	p	statistic
TFPD_d,	4.59 (2.64,	4.62.62.60.5.66	4.52 (2.59, 5.92)	0.545	24121
Median (Q1,Q3)	5.74)	4.63 (2.69, 5.66)	4.52 (2.58, 5.83)	0.545	24131
TRNBSAS_d,	4.87 (4.61,	4.90 (4.72, 6.68)	4.81 (3.61, 5.93)	0.002	20789
Median (Q1,Q3)	6.58)	4.90 (4.72, 0.08)	4.81 (3.01, 3.93)	0.002	20 <i>1</i> 89
TFFFAS_d,	4.33 ± 2.18	4.44 ± 2.04	4.16 ± 2.35	0.173	-1.356
Mean ± SD	4.33 ± 2.16	4.44 ± 2.04	4.10 ± 2.33	0.173	-1.550
TFSFAS_d,	6.77 ± 2.80	7.03 ± 2.91	6.41 ± 2.59	0.021	-2.318
Mean \pm SD	0.77 ± 2.80	7.03 ± 2.91	0.41 ± 2.39	0.021	-2.316
Postoperative					
Complications,				0.856	0.033
n (%)					
NO = 0	404 (89.0)	237 (88.8)	167 (89.3)		
YES = 1	50 (11.0)	30 (11.2)	20 (10.7)		

Notes: HCGD: History of Chronic Gastrointestinal Disease, HAS: History of 287 Abdominal Surgery, HHD: History of Heart Disease, CLD: Chronic Lung Disease, 288 TFPE: Time For First Postoperative Exhaust, TFPD: Time For First Postoperative 289 290 Defecation, TRNBSAS: Time to resuming normal bowel sounds after surgery, TFFFAS: Time For First Full-liquid Feeding After Surgery, TFSFAS: Time For First Semi-liquid 292 Feeding After Surgery.

After PSM

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

The data of 454 patients underwent propensity score matching (PSM) analysis using the nearest neighbor method, with age, tumor stage, intraoperative hemorrhage, and hyperlipidemia as matching variables. Age and hyperlipidemia were identified as potential confounding factors before matching, while tumor stage and intraoperative hemorrhage became statistically significant after adjusting for a smaller caliper value and were thus included as matching variables. The matching ratio was 1:1, with a caliper set at 0.05, resulting in successful matching of 320 patients, including 160 in the ER group and 160 in the non-ER group. Before PSM, there were significant differences between the ER and non-ER groups in terms of age and hyperlipidemia (with p-values of 0.041 and 0.008, respectively), indicating potential confounding factors. However, after PSM, the differences between the ER and non-ER groups in all characteristics became nonsignificant (all P>0.05, as detailed in Table 2), indicating successful achievement of balanced comparability after PSM. Additionally, the Jitter Plot (see Fig. 2) illustrated that, after matching, the distributions of matching variables between the ER and non-ER groups tended to be consistent, indicating a good matching effect. The Density Plot and Empirical Cumulative Distribution Function Plot (eCDF plot) (refer to S1 Fig. and S2 Fig.) demonstrated that the density curves or cumulative distribution curves of the two groups' data were close to each other after matching, further validating the effectiveness of the matching method.

As shown in Table 2, after PSM, there were statistically significant differences in postoperative gastrointestinal function recovery indicators between the two groups of patients. Compared to the ER group, the non-ER group had a shorter time to restore bowel sounds postoperatively (p=0.002) and an earlier initiation of a semi-liquid diet (p=0.022). Furthermore, compared to the ER group, the non-ER group had lower hospital costs (p<0.001) and shorter length of stay (p=0.001) (See S1 Table. for additional information).

Table 2 Baseline data after PSM

	Total	ED group	Non-ER		
Variables	Total	ER group	group	p	statistic
	(n = 320)	(n = 160)	(n = 160)		
Surgical Site, n (%)				0.818	0.053
Colon =1	122 (38.1)	62 (38.8)	60 (37.5)		
Rectum = 2	198 (61.9)	98 (61.3)	100 (62.5)		
Tumor staging, n (%)				1.127	0.771
I = 1	30 (9.4)	13 (8.1)	17 (10.6)		
II = 2	57 (17.8)	30 (18.8)	27 (16.9)		
III = 3	54 (16.9)	25 (15.6)	29 (18.1)		
unspecified = 4	179 (55.9)	92 (57.5)	87 (54.4)		
HCGD, n (%)				0.251	1.317

Variables	Total (n = 320)	ER group (n = 160)	Non-ER group (n = 160)	p	statistic
NO = 0	124 (38.8)	57 (35.6)	67 (41.9)		
YES = 1	196 (61.3)	103 (64.4)	93 (58.1)		
Intestinal Stoma,				0.545	0.266
n (%)				0.545	0.366
NO = 0	221 (69.1)	113 (70.6)	108 (67.5)		
YES = 1	99 (30.9)	47 (29.4)	52 (32.5)		
Gender, n (%)				0.575	0.314
Male = 1	171 (53.4)	88 (55.0)	83 (51.9)		
Female = 2	149 (46.6)	72 (45.0)	77 (48.1)		
CLD, n (%)				1.000	0
NO = 0	210 (65.6)	105 (65.6)	105 (65.6)		
YES = 1	110 (34.4)	55 (34.4)	55 (34.4)		
Anemia, n (%)				0.623	0.242
NO = 0	277 (86.6)	140 (87.5)	137 (85.6)		
YES = 1	43 (13.4)	20 (12.5)	23 (14.4)		
Hypoproteinemia,				1.000	0

Variables	Total (n = 320)	ER group (n = 160)	Non-ER group (n = 160)	p	statistic
n (%)					
NO = 0	302 (94.4)	151 (94.4)	151 (94.4)		
YES = 1	18 (5.6)	9 (5.6)	9 (5.6)		
HAS, n (%)				0.899	0.016
NO = 0	237 (74.1)	118 (73.75)	119 (74.4)		
YES = 1	83 (25.9)	42 (26.25)	41 (25.6)		
Diabetes, n (%)				0.741	0.110
NO = 0	278 (86.9)	140 (87.5)	138 (86.3)		
YES = 1	42 (13.1)	20 (12.5)	22 (13.8)		
Hypertension, n (%)				0.899	0.016
NO = 0	237 (74.1)	118 (73.75)	119 (74.4)		
YES = 1	83 (25.9)	42 (26.25)	41 (25.6)		
Hyperlipidemia,				1.000	0
n (%)				1.000	U
NO = 0	260 (81.25)	130 (81.25)	130 (81.25)		
YES = 1	60 (18.75)	30 (18.75)	30 (18.75)		

Variables	Total (n = 320)	ER group (n = 160)	Non-ER group (n = 160)	p	statistic
HHD, n (%)				0.228	1.455
NO = 0	220 (68.75)	105 (65.6)	115 (71.9)		
YES = 1	100 (31.25)	52 (34.4)	45 (28.1)		
Smoking History,				0.700	0.050
n (%)				0.789	0.072
NO = 0	248 (77.5)	125 (78.1)	123 (76.9)		
YES = 1	72 (22.5)	35 (21.9)	37 (23.1)		
Drinking History,				0.240	
n (%)				0.210	1.572
NO = 0	285 (89.1)	146 (91.3)	139 (86.9)		
YES = 1	35 (10.9)	14 (8.8)	21 (13.1)		
Postoperative				1 000	0
Complications, n (%)				1.000	0
NO = 0	296 (92.5)	148 (92.5)	148 (92.5)		
YES = 1	24 (7.5)	12 (7.5)	12 (7.5)		
Age,Mean \pm SD	59.99 ± 9.09	59.64 ± 9.43	60.34 ± 8.76	0.488	0.694
BMI, Mean±SD	22.89 ± 2.98	22.70 ± 3.05	23.08 ± 2.90	0.259	1.132

Variables	Total (n = 320)	ER group (n = 160)	Non-ER group (n = 160)	p	statistic
Intraoperative					
Hemorrhage_ml,	50 (50, 100)	50 (50, 100)	50 (30, 100)	0.161	11669.5
Median (Q1,Q3)					
Operative Time_h,	3.91 (3.42,	3.92(3.50,	3.90 (3.30,		
Median (Q1,Q3)	4.62)	4.65)	4.61)	0.507	12251.5
Hospital Costs_CNY,	72435.17 ±	74856.62 ±	70013.72 ±	<	
Mean±SD	10123.06	11208.38	8256.44	0.001	-4.400
Length of Hospital					
Stay_d,	15.74 ± 3.85	16.46 ± 4.048	15.01 ± 3.495	<	-3.429
Mean±SD				0.001	
NEBS,				<	
Median (Q1,Q3)	3 (0, 16)	16 (12, 19.75)	0 (0, 0)	0.001	0
TFPE_d,	1.83 (1.60,	1.86 (1.60,	1.80 (1.60,		
Median (Q1,Q3)	2.63)	2.65)	2.60)	0.195	11728.5
TFPD_d,	4.59 (2.65,	4.64 (2.78,	4.57 (2.63,		
Median (Q1,Q3)	5.73)	5.66)	5.82)	0.439	12159.5
TRNBSAS_d,	4.86 (4.57,	4.92 (4.67,	4.80 (3.55,	0.002	10219.5

Variables	Total (n = 320)	ER group (n = 160)	Non-ER group (n = 160)	p	statistic
Median (Q1,Q3)	6.36)	6.62)	5.88)		
TFFFAS_d,	4.15 + 2.05	4.22 + 1.00	2.00 + 2.10	0.120	1.522
Mean ± SD	4.15 ± 2.05	4.33 ± 1.99	3.98 ± 2.10	0.129	-1.522
TFSFAS_d,	(51 + 2.49	(01 + 2.50	(20 + 2.25	0.020	2 105
Mean ± SD	6.51 ± 2.48	6.81 ± 2.58	6.20 ± 2.35	0.030	-2.185

Fig. 2 Jitter plot of the ER group and non-ER group after PSM

Results of sensitivity analysis

The sensitivity analyses revealed that with increasing caliper values and different matching ratio conditions, the sample sizes of the matched ER and non-ER groups exhibited minimal variation. When the ratio was set to 1, as the caliper value increased from 0.02 to 0.2 (caliper values of 0.02, 0.03, 0.1, and 0.2), the sample sizes gradually increased with minor fluctuations, and the cumulative change in the number of cases did not exceed 10% of the total sample size. For instance, the number of matches for the ER and non-ER groups were 139/139, 150/150, 169/169, and 177/177, respectively. Furthermore, when the ratio was set to 2 and the caliper value was 0.05, there were 175 matches for the non-ER group and 160 matches for the ER group. After matching, all covariate p-values were greater than 0.05, indicating consistent results for each match

(see S3 Fig. and S4 Fig.).

Hence, this study demonstrates strong robustness in reaching consistent conclusions across various matching conditions, thereby enhancing the reliability and validity of the findings.

Results of the equilibrium test

The equilibrium and comparability of the two groups of data after PSM was assessed by the Standardised Mean Differences (SMD) before and after matching (see Table 3 and Fig. 3). Before matching, the SMDs of tumor stage, age and hyperlipidaemia exceeded 0.1, indicating the presence of large confounding factors. In contrast, after matching, the SMDs of potential confounders were all less than 0.1, indicating improved sample balance. In addition, the histogram (see Fig. 4) visualised that the histograms of the ER and non-ER groups showed more similar distribution patterns and locations after matching, further indicating that the two groups were more similarly distributed in terms of the characteristic variables and that the PSM was successful in reducing the propensity bias to achieve a balanced result.

Table 3 SMD before and after PSM

Before P	After PSM		
Variables	Std. Mean Diff.	Std. Mean Diff.	
Tumor staging 1	-0.0068	-0.0816	
Tumor staging 2	-0.1970	0.0520	
Tumor staging 3	0.0908	-0.0622	
Tumor staging 4	0.0735	0.0627	

Hyperlipidemia 0	-0.2388	0.0000						
Hyperlipidemia 1	0.2388	0.0000						
Age	-0.2210	-0.0685						
Intraoperative	-0.1678	0.0137						
haemorrhage_ml								
Fig. 3 SMD plot of ER group	o and non-ER group	before and after PSM						
Fig. 4 hist graph of ER group	o and non-ER group	before and after PSM						
Results of subgroup analysis								
This study categorized tumor staging into four subgroups and conducted separate statistical analyses for the ER group and non-ER group.								
	1) Tumor Stage I: Compared to the non-ER group, patients in the ER group had a							
slightly longer mean time to full-liqu								
ER: 3.66 ± 1.20 ; p=0.765), slightly longer mean time to semi-liquid diet postoperatively								
(ER: 6.87 ± 2.78 vs. non-ER: 5.70 ± 1.91 ; p=0.181), slightly longer hospital stay (ER:								
16.23 ± 3.30 vs. non-ER: 15.18 ± 2.63 ; p=0.338), and slightly higher average hospital								
costs (ER: 75132.22 ± 12657.10 vs. non-ER: 69890.67 ± 11096.58 ; p=0.238). However,								
these differences between the groups	these differences between the groups were not statistically significant (see Table 4-1).							

Table 4-1 Results of statistical analysis of dependent variables for tumor stage I

Variables	Total (n = 30)	ER group (n = 13)	Non-ER group (n = 17)	р	statistic
Hospital Costs_CNY,	72162.01 ±	75132.22 ±	69890.67 ±	0.220	1 207
Mean \pm SD	11883.00	12657.10	11096.58	0.238	-1.207
Length of Hospital	15.63 ±	16 22 + 2 20	15 10 + 2 (2	0.220	0.076
Stay_d, Mean±SD	2.93	16.23 ± 3.30	15.18 ± 2.63	0.338	-0.976
TFFFAS_d,	3.72 ± 1.20	3.79 ± 1.25	3.66 ± 1.20	0.765	-0.302
Mean ± SD					
TFSFAS_d,	6.21 ± 2.36	6.87 ± 2.78	5.70 ± 1.91	0.181	-1.373
$Mean \pm SD$					
Postoperative				1.00	Fisher's
Complications, n (%)	ons, n (%)				exact test
NO = 0	27 (90.0)	12 (92.3)	15 (88.2)		
YES = 1	3 (10.0)	1 (7.7)	2 (11.8)		

2) Tumor stage II: Except for hospital costs, patients in the ER group had a shorter mean time to full-liquid diet after surgery (ER: 4.15 ± 1.05 vs non-ER: 5.05 ± 3.11 ; p=0.161), a shorter average time to semi-liquid diet after surgery (ER: 6.40 ± 1.21 vs non-ER: 7.35 ± 3.51 ; p=0.191), and a shorter average hospital costs (ER: 75576.01 ± 10654.74 vs non-ER: 73310.87 ± 7431.45 ; p=0.361), and shorter average hospital stay (ER: 16.47 ± 2.69 vs. non-ER: 16.78 ± 4.68 ; p=0.756) compared to the non-ER group,

although these differences were not statistically significant between groups (see Table4-2).

Table 4-2 Results of statistical analysis of dependent variables for tumor stage II

Variables	Total (n = 57)	ER group $(n = 30)$	Non-ER group	p	statistic
			(n = 27)		
Hospital	74503.05 ±	75576.01 ±	73310.87 ±		
Costs_CNY,			73310.87 ±	0.361	-0.921
Mean±SD	9259.14	10654.74	7431.45		
Length of Hospital					
Stay_d,	16.61 ± 3.73	16.47 ± 2.69	16.78 ± 4.68	0.756	0.312
Mean ± SD					
TFFFAS_d, Mean±SD	4.57 ± 2.30	4.15 ± 1.05	5.05 ± 3.11	0.161	1.437
TFSFAS_d,	6.95 + 2.50	6.40 + 1.21	7.25 + 2.51	0.101	1 225
Mean \pm SD	6.85 ± 2.59	6.40 ± 1.21	7.35 ± 3.51	0.191	1.335
Postoperative				1.000	Fisher's
Complications, n (%)				1.000	exact test
NO = 0	53 (93.0)	28 (93.3)	25 (92.6)		
YES = 1	4 (7.0)	2 (6.7)	2 (7.4)		

3) Tumor stage III and unspecified stage: According to Table 4-3, compared with the ER group, the non-ER group had a significantly shorter postoperative time to semiliquid diet (ER: 8.35 ± 4.19 vs. non-ER: 6.45 ± 2.33), with a statistically significant difference between the two groups (p=0.041); as shown in Table 4-4, compared with the ER group, the non-ER group not only had a significantly shorter postoperative time to semi-liquid diet (ER: 6.51 ± 2.18 vs. non-ER: 5.87 ± 1.85 ; p=0.034), but also had significantly lower hospital costs (ER: 75510.44 ± 11584.95 vs. non-ER: 69478.08 ± 7643.31 ; p<0.001) and shorter hospital stays (ER: 16.29 ± 3.957 vs. non-ER: 14.47 ± 3.154 ; p<0.001), with significant statistical differences between the two groups.

Table 4-3 Results of statistical analysis of dependent variables for tumor stage III

	T-4-1	ΓD	Non-ER		
Variables	Total $(n = 54)$	ER group $(n = 25)$	group (n = 29)	p	statistic
Hospital Costs_CNY,	69929.01 ±	71443.97 ±	68623.01 ±	0.257	1.146
Mean ± SD	9049.86	9574.28	8522.77	0.257	-1.146
Length of Hospital Stay_d, Mean±SD	15.96 ± 4.74	17.20 ± 5.86	14.90 ± 3.26	0.075	-1.818
TFFFAS_d, Mean±SD	4.52 ± 2.20	5.10 ± 2.52	4.01 ± 1.79	0.069	-1.855
TFSFAS_d, Mean±SD	7.33 ± 3.43	8.35 ± 4.19	6.45 ± 2.33	0.041	-2.096

Variables	Total (n = 54)	ER group $(n = 25)$	Non-ER group (n = 29)	p	statistic
Postoperative				1.000	Fisher's exact
Complications, n (%)				1.000	test
NO = 0	49 (90.7)	23 (92.0)	26 (89.7)		
YES = 1	5 (9.3)	2 (8.0)	3 (10.3)		

Table 4-4 Results of statistical analysis of the dependent variable for tumor stage as

unspecified stage

387

			Non-ER		
Variables	Total (n = 179)	ER group (n = 92)	group (n = 87)	p	statistic
Hospital Costs_CNY, Mean±SD	72578.51± 10294.67	75510.44 ± 11584.95	69478.08 ± 7643.31	< 0.001	-4.133
Length of Hospital $Stay_d$, $Mean \pm SD$	15.41 ± 3.694	16.29 ± 3.957	14.47± 3.154	< 0.001	-3.416
TFFFAS_d, Mean \pm SD	3.98 ± 2.01	4.25 ± 2.11	3.69 ± 1.86	0.066	-1.853
TFSFAS_d, Mean±SD	6.20 ± 2.04	6.51 ± 2.18	5.87 ± 1.85	0.034	-2.131

Variables	Total (n = 179)	ER group (n = 92)	Non-ER group (n = 87)	p	statistic
Postoperative					Fisher's exact
Complications,				0.768	test
n (%)					CSI
NO = 0	167 (93.3)	85 (92.4)	82 (94.3)		
YES = 1	12 (6.7)	7 (7.6)	5 (5.7)		

Discussion

ER is characterised by its pungent nature and spicy, bitter taste with low toxicity. From a traditional Chinese medicine review, it is associated with the liver, spleen, stomach, and kidney meridians. Its effects include dispersing cold and relieving pain, reducing rebellious qi and stopping vomiting, and aiding yang tonification and stopping diarrhoea^[29]. The "Shennong Bencao Jing" also describes ER as a mildly warm herb, mainly used for warming the middle, dispelling cold, removing dampness and blood stasis, expelling wind evil and opening the body channels, and classifies it as a medium-grade herb^[16].

The Shen Que acupoint of the Ren meridian is located at the navel. The Ren meridian, one of the eight extraordinary meridians, intersects with the twelve ordinary meridians and serves as the hub of the meridian system, connecting hundreds of vessels and penetrating the five zang organs and six fu organs^[30-31]. Applying medicine to the

navel can promote circulation in the meridians, harmonise abdominal qi and relieve abdominal bloating and discomfort^[31]. Modern research has found that during embryonic development, the navel is the final site of closure of the abdominal wall, lacking subcutaneous fat but containing abundant blood vessels, lymphatic vessels and nerves, making it highly permeable^{[32-} ^{34]}. Therefore, drug molecules can easily penetrate the epidermal keratin layer of the umbilicus, rapidly infiltrate the intercellular space and exert their effects. In clinical practice, the commonly used ER hot compress therapy uses local heat to facilitate the penetration of drugs such as evodiamine and rutaecarpine from the ER into the abdomen (around the navel) to accelerate the recovery of post-operative gastrointestinal function^[35-36]. This retrospective cohort study aimed to investigate the effects of using ER hot compress therapy on the recovery of gastrointestinal (GI) function in patients undergoing colorectal cancer surgery. Currently, most retrospective cohort studies tend to directly analyse the raw data to verify the effectiveness of ER hot compress therapy. However, due to limitations in study design, those studies suffer from recall bias and multiple confounding factors that do not adequately account for the importance of ER hot compress therapy in the recovery of postoperative gastrointestinal function. To reduce these confounding factors, this study adopted the PSM method, which is commonly used in clinical practice, and investigated the factors that influence the efficacy of ER hot compresses. At the same time, a subgroup analysis according to tumor stage was performed to gain insight into the use of the method in patients with

403

404

405

406

407

408

409

410

411

412

413

414

415

416

417

418

419

420

421

422

423

different stages of the disease.

425

426

427

428

429

430

431

432

433

434

435

436

437

438

439

440

441

442

443

444

445

446

The results of our study showed that when comparing patients in the ER and non-ER groups, the matched results showed that there was no significant difference between the two groups in terms of indicators related to gastrointestinal function after laparoscopic surgery (p-values were all greater than 0.05), which was similar to the results of the studies by Chen^[37] and Jian^[38]. Interestingly, however, when analysing the tumor stage into subgroups according to the AJCC TNM system^[28], we found that the mean postoperative recovery time on a full-liquid diet was shorter in the ER group for patients with tumor stage II compared to the non-ER group (non-ER group: $5.05 \pm$ 3.11 vs. ER group: 4.15 ± 1.05), the mean recovery time on semi-liquid diet was also shorter (non-ER group: 7.35 ± 3.51 vs. ER group: 6.40 ± 1.21), and the mean length of hospital stay was also shorter (non-ER group: 16.78 ± 4.68 vs. ER group: 16.47 ± 2.69). Although not statistically significant, these findings imply that patients with different tumor stages may differ in the therapeutic efficacy of ER hot compress therapy, suggesting that postoperative patients with early-stage tumors may be a potential population to benefit from ER hot compress therapy. In addition, the combination of ER hot compress therapy with other complementary and alternative therapies has been widely used after a variety of abdominal surgeries^[39-43]. These therapies include pain management^[44], ultrasound electroconductive transdermal drug delivery techniques^[45], moxibustion^[46], auricular acupressure and electroacupuncture^[47-48]. The results of clinical studies have shown that ER hot compress therapy combined with other therapies can not only improve the

symptoms of urinary retention, nausea and vomiting, abdominal distension and abdominal pain in postoperative patients, but also promote the recovery of gastrointestinal function in postoperative patients. However, because more than two alternative therapies were combined, it was not possible to determine exactly which therapy had a significant effect. Furthermore, although previous studies have explored the impact of different treatment options on patient recovery, few studies have analysed the cost-effectiveness of patients receiving complementary and alternative therapies from an economic perspective, especially when looking at hospital costs and treatment outcomes. Therefore, our study filled the gap in previous research by conducting an in-depth analysis of the cost-effectiveness of patients receiving complementary and alternative therapies from an economic perspective. With a focus on assessing the economic impact of these therapies, particular attention was paid to hospital costs, the length of hospital stay and treatment outcomes. Our results indicate that patients receiving ER hot compress therapy showed an overall increasing trend in hospital costs. However, further analysis showed that there were no significant differences in hospital costs and the length of hospital stay between the ER and non-ER groups in different tumor stage subgroups (including tumor stages I and II as well as stage III), with p-values all greater than 0.2. Additionally, the length of hospital stay was not statistically significant for patients with tumor stage I or II (p > 0.1). This finding suggests that although receiving ER hot compress therapy may slightly increase overall patient costs, there was no apparent economic disadvantage within specific subgroups. Therefore, our study

447

448

449

450

451

452

453

454

455

456

457

458

459

460

461

462

463

464

465

466

467

highlights the considerations that healthcare practitioners need to address how to effectively use treatment modalities and techniques to improve patient recovery rates and reduce hospital length of stay without significantly increasing patient costs.

Limitations

469

470

471

472

473

474

475

476

477

478

479

480

481

482

483

484

485

486

487

488

489

490

The limitations of this study may include: (1) due to inherent methodological limitations of retrospective study, the accuracy of recording time of first postoperative flatus, first postoperative defecation and recovery of postoperative bowel sound was limited, which may have led to bias in the assessment of recovery of postoperative gastrointestinal function, potentially affecting the reliability of the study conclusions. (2) there was no statistical analysis of the differences in surgical experience between surgeons, nor was there a detailed investigation of potential confounding factors such as age and gender. (3) some objective laboratory indicators to validate the efficacy of ER hot compress therapy were not included. (4) the frequency of use of ER hot compress therapy by patients was not discussed and the effect of frequency of use on efficacy remains unclear. In addition, there may have been variability in the implementation of ER hot compress therapy. (5) patients were not followed up, which might limit understanding of post-discharge outcomes. (6) selection bias could not be avoidedi.e. patients with more severe conditions are more likely to choose complementary and alternative therapies such as ER hot compress therapy. This may lead to selection bias and might affect the results of the trial.

Therefore, we recommend the following.

First, plarger sample sizes, multicentre controlled prospective cohort studies or

randomised controlled trials are recommended. Second, future clinical studies on ER hot compress therapy should explicitly state that the treatment team's characteristics and the experiences of the surgeon to better control for potential confounding factors. Third, the objective experimental indicators should be selected and not limited to comparing the recovery of gastrointestinal function during hospitalisation after surgery, follow-up observations, such as rehospitalisation rates and outpatient follow-up, should be included to complement the assessment of postoperative recovery of gastrointestinal function. Fourth, future studies should provide a more detailed record of the frequency of ER hot compress therapy usage and explore how usage frequency affects treatment efficacy. If possible, the overall effects on the recovery of postoperative gastrointestinal function of different groups should be compared by follow-up after discharge. Finally, future studies can employ qualitative research methods, such as interviewing patients about their experiences of postoperative use of ER hot compress therapy, to comprehensively evaluate the clinical benefits of this complementary and alternative therapy.

Conclusion

491

492

493

494

495

496

497

498

499

500

501

502

503

504

505

506

507

508

509

510

511

512

The overall comparison suggests that Evodia rutaecarpa (ER) hot compress therapy may not significantly promote recovery of gastrointestinal function, however, patients with early-stage colorectal cancer may be a potential beneficiary group. Therefore, healthcare providers should consider treatment diversity and patient characteristics when formulating personalised treatment plans. By developing

treatment regimes based on scientific evidence and individual patient needs, healthcare professionals can optimise treatment outcomes and effectively meet patient needs. **Acknowledgments** We would like to thank Mr. XiaoFeng Chen for his technical support and guidance. **Supporting information** S1 File. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines. S1 Fig. The density plot of the ER group and non-ER group before and after PSM. S2 Fig. The eCDF plot of the ER group and non-ER group before and after PSM. S3 Fig. Differences in standard deviation plots of the ER group and non-ER group before and after PSM under different caliper values. S4 Fig. Histograms of the ER group and non-ER group before and after PSM at different caliper values. S1 Table. The 95% confidence intervals for continuous variables before and after PSM. S2 Table. Types of postoperative complications. Reference [1] World Health Organization (WHO). Global cancer burden growing, amidst mounting need for services. [Accessed on 01 February 2024]. Available online:

513

514

515

516

517

518

519

520

521

522

523

524

525

526

527

528

529

530

531

532

- https://www.who.int/news/item/01-02-2024-global-cancer-burden-growing-amidst-mounting-need-for-services
- [2]World Health Organization. The Global Cancer Observatory: 2022 [Internet].
 World Health Organization; 2024 Feb 8. Available from:
 https://gco.iarc.who.int/media/globocan/factsheets/cancers/8-colon-fact-sheet.pdf
- [3]Garg R, Sayre EC, Pataky R, McTaggart-Cowan H, Peacock S, Loree JM, McKenzie M, Brown CJ, Yeung SST, De Vera MA. Direct Medical Spending on Young and Average-Age Onset Colorectal Cancer before and after Diagnosis: a Population-Based Costing Study. Cancer Epidemiol Biomarkers Prev. 2024 Jan 9;33(1):72-79. doi: 10.1158/1055-9965.EPI-23-0498. PMID: 37878338; PMCID: PMC10774739.
- [4]Qu R, Ma Y, Zhang Z, Fu W. Increasing burden of colorectal cancer in China. Lancet Gastroenterol Hepatol. 2022 Aug;7(8):700. doi: 10.1016/S2468-1253(22)00156-X. PMID: 35809603.
- [5]Li S, Liu KX, Deng XM, Fang XM, Xia ZY, Wang YL, Yu JB, Li JB, Shang Y, Zhou J. Expert consensus on prevention and treatment of postoperative gastrointestinal dysfunction. *Journal of International Anesthesiology and Resuscitation*. 2021;42(11):1133-1142. DOI:10.3760/cma.j.cn321761-20210811-10003.
- [6]Feng R, Su Q, Huang X, Basnet T, Xu X, Ye W. Cancer situation in China: what does the China cancer map indicate from the first national death survey to the latest cancer registration? Cancer Commun (Lond). 2023 Jan;43(1):75-86. doi: 10.1002/cac2.12393. Epub 2022 Nov 17. PMID: 36397729; PMCID:

PMC9859730.

- [7] Wang Z, Dan W, Zhang N, Fang J, Yang Y. Colorectal cancer and gut microbiota studies in China. Gut Microbes. 2023 Jan-Dec;15(1):2236364. doi: 10.1080/19490976.2023.2236364. PMID: 37482657; PMCID: PMC10364665.
- [8] Abualkhair WH, Zhou M, Ahnen D, Yu Q, Wu XC, Karlitz JJ. Trends in Incidence of Early-Onset Colorectal Cancer in the United States Among Those Approaching Screening Age. JAMA Netw Open. 2020 Jan 3;3(1):e1920407. doi: 10.1001/jamanetworkopen.2019.20407. Erratum in: JAMA Netw Open. 2020 Feb 5;3(2):e201038. PMID: 32003823; PMCID: PMC7042874.
- [9]GBD 2019 Colorectal Cancer Collaborators. Global, regional, and national burden of colorectal cancer and its risk factors, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Gastroenterol Hepatol. 2022 Jul;7(7):627-647. doi: 10.1016/S2468-1253(22)00044-9. Epub 2022 Apr 7. Erratum in: Lancet Gastroenterol Hepatol. 2022 Aug;7(8):704. PMID: 35397795; PMCID: PMC9192760.
- [10]Burnett-Hartman AN, Lee JK, Demb J, Gupta S. An Update on the Epidemiology, Molecular Characterization, Diagnosis, and Screening Strategies for Early-Onset Colorectal Cancer. Gastroenterology. 2021 Mar;160(4):1041-1049. doi: 10.1053/j.gastro.2020.12.068. Epub 2021 Jan 5. PMID: 33417940; PMCID: PMC8273929.
- [11]Spaander MCW, Zauber AG, Syngal S, Blaser MJ, Sung JJ, You YN, Kuipers EJ. Young-onset colorectal cancer. Nat Rev Dis Primers. 2023 Apr 27;9(1):21. doi: 10.1038/s41572-023-00432-7. PMID: 37105987; PMCID: PMC10589420.
- [12]Siegel RL, Wagle NS, Cercek A, Smith RA, Jemal A. Colorectal cancer statistics, 2023. CA Cancer J Clin. 2023 May-Jun;73(3):233-254. doi:

- 10.3322/caac.21772. Epub 2023 Mar 1. PMID: 36856579.
- [13]Half EE, Levi Z, Mannalithara A, Leshno M, Ben-Aharon I, Abu-Freha N, Silverman B, Ladabaum U. Colorectal cancer screening at age 45 years in Israel: Cost-effectiveness and global implications. Cancer. 2024 Mar 15;130(6):901-912. doi: 10.1002/cncr.35097. Epub 2024 Jan 5. PMID: 38180788.
- [14] Howren A, Sayre EC, Loree JM, Gill S, Brown CJ, Raval MJ, Farooq A, De Vera MA. Trends in the Incidence of Young-Onset Colorectal Cancer With a Focus on Years Approaching Screening Age: A Population-Based Longitudinal Study. J Natl Cancer Inst. 2021 Jul 1;113(7):863-868. doi: 10.1093/jnci/djaa220. PMID: 33492399; PMCID: PMC8246802.
- [15]Jiang T, Li J, Meng L, Wang J, Zhang H, Liu M. Effects of transcutaneous electrical acupoint stimulation on gastrointestinal dysfunction after gastrointestinal surgery: A meta-analysis. Complement Ther Med. 2023 May;73:102938. doi: 10.1016/j.ctim.2023.102938. Epub 2023 Feb 25. PMID: 36842636.
- [16]Li AY. Shennong's Classic of Materia Medica (Illustrated Edition). Beijing: Minzhu yu jianshe chubanshe; 2021: 207.
- [17]World Health Organization. WHO traditional medicine strategy: 2014-2023 [Internet]. World Health Organization; 2013 May 15. Available from: https://www.who.int/publications/i/item/9789241506096
- [18]Li DT, Wu XZ, He JL, Tang HM, Zhang LJ, Qiu ZW. Transdermal Drug Release Characteristics of Wuzhuyu Alkaloids and Wuzhuyu Alkaloids Determined by in vivo Skin Microdialysis Technique and HPLC. Chin Pharm J. 2015;03:239-243.

- [19]Gu Q, Wei XC, Liu L, Liang Y, Li J, Dong J, Cai XY, Gu W, Chen J.
 Exploration of the Pharmacological Substance Basis and Potential Molecular
 Mechanism of External Application of Volatile Oil of Pungent and Hot
 Chinese Medicine Based on Network Pharmacology. Chin Tradit Herb Drugs.
 2021;05:1383-1392.
- [20]von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP; STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. PLoS Med. 2007 Oct 16;4(10):e296. doi: 10.1371/journal.pmed.0040296. PMID: 17941714; PMCID: PMC2020495.
- [21]STROBE. STROBE Checklist: cohort studies [Internet]. [Accessed in 2024].

 Available from: https://www.strobe-statement.org/checklists/
- [22]National Health Commission of the People's Republic of China; Chinese Society of Oncology. [Chinese Protocol of Diagnosis and Treatment of Colorectal Cancer (2023 edition)]. Zhonghua Wai Ke Za Zhi. 2023 Aug 1;61(8):617-644. Chinese. doi: 10.3760/cma.j.cn112139-20230603-00222. PMID: 37400205.
- [23]Duhamel A, Labreuche J, Gronnier C, Mariette C. Statistical Tools for Propensity Score Matching. Ann Surg. 2017;265(6):E79-E80. doi:10.1097/SLA.0000000000001312
- [24]Bangalore S, Guo Y, Samadashvili Z, Blecker S, Xu J, Hannan EL. Everolimus-eluting stents or bypass surgery for multivessel coronary disease. N Engl J Med. 2015;372(13):1213-1222. doi:10.1056/NEJMoa1412168
- [25]Gu HQ. Statistical approaches and figures for sensitivity analysis in clinical research: a systematic review. Chin J Evid-Based Cardiovasc Med. 2018. doi:

- 10.3969/j.issn.1674-4055.2018.10.04.
- [26] Austin PC. The relative ability of different propensity score methods to balance measured covariates between treated and untreated subjects in observational studies. Med Decis Making. 2009 Nov-Dec;29(6):661-77. doi: 10.1177/0272989X09341755. Epub 2009 Aug 14. PMID: 19684288.
- [27] Austin PC. An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies. Multivariate Behav Res. 2011 May;46(3):399-424. doi: 10.1080/00273171.2011.568786. Epub 2011 Jun 8. PMID: 21818162; PMCID: PMC3144483.
- [28]Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010 Jun;17(6):1471-4. doi: 10.1245/s10434-010-0985-4. PMID: 20180029.
- [29] Chinese Pharmacopoeia Commission. Chinese Pharmacopoeia [Internet]. 10th ed. Beijing: China Medical Science Press; 2020 [cited 2024 Mar 20].
- [30]Liang BX, Yuan TH, Yan C, Wang LJ, Xian SX. On the Traditional Chinese Medicine Connotation of Navel Therapy. Chin J Tradit Chin Med. 2018;10:4329-4332.
- [31]Liang C, Deng HY, Zheng LP, Liu D, Zhang YJ, Wu XF, Yuan JH. [Clinical observation of traditional Chinese medicine application on umbilical region for treating opioid-induced constipation]. Chin J Clin Physician. 2017;45(7):119-121.
- [32]Li YH, Tao J. The effect of abdominal acupoint application therapy on the recovery of gastrointestinal function in patients with acute intestinal obstruction.
 Modern Journal of Integrated Traditional Chinese and Western Medicine.

- 2020;(01):87-91.
- [33]Lv SW, Pan SW, Fu QF, Guo YY, Sun S, Li YJ. Development overview and prospects of navel drug delivery formulations. Chin J Tradit Chin Med. 2015;06:109-112. doi:10.19664/j.cnki.1002-2392.2015.06.037.
- [34]Feng L, Ding MH, Shen Q, Sun QH, Shi SL. Factors affecting the percutaneous permeability of rhein at the Shenque acupoint: a study on preliminary mechanisms. Chin J Tradit Chin Med. 2016;08:1546-1552.
- [35]Li X, Shen Y, Pan G, Peng H. Effects of moxibustion with Wuzhuyu on gastrointestinal motility and gastrointestinal hormone secretion in patients after abdominal surgery. J Anhui Univ Chin Med. 2024;02:28-31.
- [36]Wang S, Lei XJ, Zhu WF, Huang ZG. Study on in vitro percutaneous absorption of vinegar-modified Wu Zhu Yu powder. Chin J Exp Tradit Med Form. 2013;10:31-34.
- [37]Chen Z, Cao L, Wen Z, Cui N, Li N, Xie J, Tan Z, Luo Z, Wang S, Qin Y, Chen X, Xu Z, Ou A, Shang W, Jiang Z, Chen Q. Study of Evodia hot compress plus electro-acupuncture in patients who have undergone abdominal surgery. Int J Clin Exp Med. 2015 Sep 15;8(9):16167-74. PMID: 26629130; PMCID: PMC4659019.
- [38]Jian L. Application of Traditional Chinese Medicine External Treatment in the Combination of Laparoscopic and Open Surgery for Rapid Recovery Surgery in Colorectal Cancer [master's thesis]. Guangzhou University of Chinese Medicine; 2010. Available from: https://kns.cnki.net/kcms2/article/abstract?v=eoCTaIZmBOOIo2BJaiSkM9x5 UbJWb3bIFw3CQ_YnXnl9HVFsAG_0tChqZ1cSOuYxqOmNeUDGmxlpvo1 Iey1-JOTRJHj5PUwJKC0wu97m52osQoRbfKb38C-

- SR2MWo6lnqxtUSxU1BV4vsVU0FUmkyA==uniplatform=NZKPTlanguage =CHS.
- [39]Wu JP, Ouyang FJ, Li ZS, Wu YR. Observation on the Effect of Enhanced Recovery Surgical Nursing Combined with Wuzhuyu Hot Compress External Application on Patients after Laparoscopic Appendectomy. J Baotou Med Coll. 2020;11:86-89. doi:10.16833/j.cnki.jbmc.2020.11.024
- [40]Yu J, Zhang ZJ, Liu YR. Effects of external application of Wuzhuyu on gastrointestinal function and inflammatory markers in patients after colon cancer surgery. J External Ther Tradit Chin Med. 2021;06:7-8.
- [41]Zhu CH, Zhou ZZ. Effects of wuzhuyu fumigation combined with acupoint massage on postoperative abdominal distention and pain in patients with uterine fibroids undergoing laparoscopic surgery. J Jiangxi Univ Tradit Chin Med. 2022;05:56-59.
- [42]Wen HJ, Wang JH, Zeng MF, Tan FN, Xie WJ. Effects of meridian acupoint massage combined with Wuzhuyu coarse salt hot compress on gastrointestinal function recovery after rectal cancer surgery. Syst Med. 2023;20:124-127. doi:10.19368/j.cnki.2096-1782.2023.20.124.
- [43]Li L, Wei RL, Cao H, Wei LJ, Shen JW, Sun M, Wang GL. Effects of Wuzhuyu coarse salt hot compress on gastrointestinal function recovery in patients with colorectal cancer after surgery under the guidance of enhanced recovery surgical concept. Colorectal Anal Surg. 2021;5:508-510+514. doi:10.19668/j.cnki.issn1674-0491.2021.05.025.
- [44]Zhang LQ, Zhang QS, Hu Y. Application of Pain Care Combined with Wuzhuyu Hot Compress in Postoperative Patients of Urological Laparoscopy. Gen Nurs. 2015;24:2374-2376.

- [45]Li LQ, Luo JY, Zhou XD, Chen PQ, Hu HQ, Liu Y, Zhang LJ. Efficacy analysis of hot compress with Evodia rutaecarpa combined with ultrasonic conductivity meter in promoting gastrointestinal function recovery in patients undergoing gastrointestinal surgery. Med Pharm High Vocat Educ Mod Nurs. 2023;(06):500-502+507.
- [46]Xu LG. Perioperative Application of Moxibustion and Hot Compress in Laparoscopic Cholecystectomy. J Pract Tradit Chin Med. 2013;03:150-153.
- [47]Chen Y, Gan Q, Zhang YH, Tang LP, Xiong ZF. Application effect of wuzhuyu hot compress combined with ear acupoint pressing beans in patients after laparoscopic surgery in urology department. J Pract Clin Med. 2023;06:74-77+91. doi:10.13764/j.cnki.lcsy.2023.06.019.
- [48]Qu HH, Qu XL, Li M. Study on the efficacy of Wuzhuyu abdominal hot compress combined with acupuncture at Zusanli point in promoting rapid recovery after laparoscopic surgery for colorectal cancer. Chin J Med Pharm. 2021;06:175-177+181.

533

534

535

536

537

A total of 1,480 inpatients diagnosed with colorectal cancer in the SAHGUCM from December 2016 to December 2022 were retrieved.




Fig. 1

Distribution of Propensity Scores




Fig. 2




Fig. 3




Fig. 4